Peter M. Small, MD Named to Board of Directors of Aeras Global TB Vaccine Foundation
Posted on: Wednesday, 11 July 2007, 18:02 CDT
ROCKVILLE, Md., July 11 /PRNewswire-USNewswire/ -- The Aeras Global TB Vaccine Foundation, a non-profit organization working through public-private partnerships to develop new vaccines against tuberculosis, announces the appointment of Peter M. Small, MD, to its Board of Directors. Dr. Small has done extensive research in the field of infectious diseases, with a particular focus on tuberculosis.
"Dr. Small has made significant contributions to our understanding of the molecular epidemiology of this deadly disease and our ability to develop tools to control it," said Chairman of the Board, Dr. R. Gordon Douglas, Jr. "His knowledge and dedication will be invaluable to Aeras' vaccine development efforts."
Dr. Small is a Senior Program Officer for Tuberculosis at the Bill & Melinda Gates Foundation, where he is responsible for developing and implementing the foundation's tuberculosis activities. He is also a Professor at the Institute of Systems Biology, where his laboratory is focused on the use of molecular biology tools to examine the genome of Mycobacterium tuberculosis (M.tb) to answer fundamental questions about its ecology and evolution.
Immediately prior to joining the Bill & Melinda Gates Foundation, he was on the faculty of Stanford University's Division of Infectious Disease and Geographic Medicine where he was actively involved in research, teaching and patient care. His research has focused on the nature and consequences of genetic variability within the species of M.tb and has involved collaborative efforts with basic scientists, public health officials and clinicians to use new molecular biology tools coupled with epidemiology to address pragmatic questions about the control of tuberculosis. This work included population based field research projects in Latin America, Africa, Asia and Europe.
Dr. Small served as a member of the Institute of Medicine's committee addressing the elimination of tuberculosis in the United States and currently serves as a member of the WHO Stop TB Coordinating Board. In 2002 he was awarded the Princess Chichibu Global Tuberculosis Award for his pioneering contributions to global tuberculosis control.
Dr. Small trained in internal medicine at the University of California San Francisco, where he was the Chief Medical Resident at San Francisco General Hospital, and infectious diseases at Stanford University.
About Aeras
Aeras Global TB Vaccine Foundation (http://www.aeras.org/) is a non-profit organization working as a Product Development Partnership to develop new tuberculosis vaccines and ensure that they are distributed to all who need them around the world. Dr. Jerald C. Sadoff, President and CEO of Aeras, has worked in vaccine development for more than 30 years. He has been involved in efforts to develop and obtain licensure for nine currently licensed vaccines. Aeras is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs, the Danish International Development Agency, and the U.S. Centers for Disease Control and Prevention. Aeras is based in Rockville, Maryland.
Aeras Global TB Vaccine Foundation
CONTACT: Jennifer Woolley of Aeras Global TB Vaccine Foundation,+1-301-547-2942, media@aeras.org
Web site: http://www.aeras.org/
Source: PRNewswire-USNewswire
Related Articles
- ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tolls for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
- Examine This Global Vaccine Market Forecast to 2012 As the Market is Expected to Emerge As the Fastest Growing Therapy Area in the Next 5 Years
- Small Town and Rural Development Part of Consumers Energy's 'Growing Forward' Business Strategy
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- Ryan Wartena, Ph.D., VP Research, Engineering and Development of Nano Sol Systems, Inc., Named to Watts Up America Advisory Board
- Celera and Ipsen Enter Research Collaboration to Develop Pharmacogenomic Tests
- Ardea Biosciences, Inc. Announces Appointment of Patrick M. O'Connor As Senior Vice President of Research and Preclinical Development and Chief Scientific Officer
- Global Vaccine Market Projected to Reach US$ 21.05 Billion By 2010 From US$ 11.42 Billion in 2006
- Taiwanese Researchers Work to Develop Anti-Fear Drug
- Development Control Casebook Forum
 |
 |
User Comments (0)
RSS Feeds